Literature DB >> 30382303

Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease.

Fabrizio De Carli1, Flavio Nobili2, Marco Pagani3,4, Matteo Bauckneht5,6, Federico Massa2, Matteo Grazzini2, Cathrine Jonsson4, Enrico Peira7, Silvia Morbelli5,6, Dario Arnaldi2.   

Abstract

PURPOSE: The aim of this study was to verify the reliability and generalizability of an automatic tool for the detection of Alzheimer-related hypometabolic pattern based on a Support-Vector-Machine (SVM) model analyzing 18F-fluorodeoxyglucose (FDG) PET data.
METHODS: The SVM model processed metabolic data from anatomical volumes of interest also considering interhemispheric asymmetries. It was trained on a homogeneous dataset from a memory clinic center and tested on an independent multicentric dataset drawn from the Alzheimer's Disease Neuroimaging Initiative. Subjects were included in the study and classified based on a diagnosis confirmed after an adequate follow-up time.
RESULTS: The accuracy of the discrimination between patients with Alzheimer Disease (AD), in either prodromal or dementia stage, and normal aging subjects was 95.8%, after cross-validation, in the training set. The accuracy of the same model in the testing set was 86.5%. The role of the two datasets was then reversed, and the accuracy was 89.8% in the multicentric training set and 88.0% in the monocentric testing set. The classification rate was also evaluated in different subgroups, including non-converter mild cognitive impairment (MCI) patients, subjects with MCI reverted to normal conditions and subjects with non-confirmed memory concern. The percent of pattern detections increased from 77% in early prodromal AD to 91% in AD dementia, while it was about 10% for healthy controls and non-AD patients.
CONCLUSIONS: The present findings show a good level of reproducibility and generalizability of a model for detecting the hypometabolic pattern in AD and confirm the accuracy of FDG-PET in Alzheimer disease.

Entities:  

Keywords:  Alzheimer disease; Classification and prediction; Discriminant analysis; FDG-PET; MCI due to AD; Neurodegenerative disorders; Neuroimage classification; Support vector machine

Mesh:

Substances:

Year:  2018        PMID: 30382303     DOI: 10.1007/s00259-018-4197-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

3.  Likelihood ratios with confidence: sample size estimation for diagnostic test studies.

Authors:  D L Simel; G P Samsa; D B Matchar
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

4.  Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test.

Authors:  Lejla Hotilovac
Journal:  Stat Methods Med Res       Date:  2008-04       Impact factor: 3.021

5.  Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer's disease: a study using positron emission tomography with fluorodeoxyglucose-F18.

Authors:  Roland Zahn; Freimut Juengling; Philine Bubrowski; Elke Jost; Petra Dykierek; Jochen Talazko; Michael Huell
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

6.  Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project.

Authors:  Silvia Morbelli; Alex Drzezga; Robert Perneczky; Giovanni B Frisoni; Anna Caroli; Bart N M van Berckel; Rik Ossenkoppele; Eric Guedj; Mira Didic; Andrea Brugnolo; Gianmario Sambuceti; Marco Pagani; Eric Salmon; Flavio Nobili
Journal:  Neurobiol Aging       Date:  2012-02-23       Impact factor: 4.673

7.  Self-reported memory complaints: implications from a longitudinal cohort with autopsies.

Authors:  Richard J Kryscio; Erin L Abner; Gregory E Cooper; David W Fardo; Gregory A Jicha; Peter T Nelson; Charles D Smith; Linda J Van Eldik; Lijie Wan; Frederick A Schmitt
Journal:  Neurology       Date:  2014-09-24       Impact factor: 9.910

Review 8.  Mild cognitive impairment: an overview.

Authors:  Ronald C Petersen; Selamawit Negash
Journal:  CNS Spectr       Date:  2008-01       Impact factor: 3.790

9.  Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD.

Authors:  Dario Arnaldi; Silvia Morbelli; Andrea Brugnolo; Nicola Girtler; Agnese Picco; Michela Ferrara; Jennifer Accardo; Ambra Buschiazzo; Fabrizio de Carli; Marco Pagani; Flavio Nobili
Journal:  Parkinsonism Relat Disord       Date:  2016-05-30       Impact factor: 4.891

10.  Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping.

Authors:  M Signorini; E Paulesu; K Friston; D Perani; A Colleluori; G Lucignani; F Grassi; V Bettinardi; R S Frackowiak; F Fazio
Journal:  Neuroimage       Date:  1999-01       Impact factor: 6.556

View more
  4 in total

1.  Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer's disease with FDG-PET.

Authors:  Dominik Blum; Inga Liepelt-Scarfone; Daniela Berg; Thomas Gasser; Christian la Fougère; Matthias Reimold
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

2.  Heuristic scoring method utilizing FDG-PET statistical parametric mapping in the evaluation of suspected Alzheimer disease and frontotemporal lobar degeneration.

Authors:  Jeremy N Ford; Elizabeth M Sweeney; Myrto Skafida; Shannon Glynn; Michael Amoashiy; Dale J Lange; Eaton Lin; Gloria C Chiang; Joseph R Osborne; Silky Pahlajani; Mony J de Leon; Jana Ivanidze
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-08-15

3.  FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.

Authors:  Ya-Nan Ou; Wei Xu; Jie-Qiong Li; Yu Guo; Mei Cui; Ke-Liang Chen; Yu-Yuan Huang; Qiang Dong; Lan Tan; Jin-Tai Yu
Journal:  Alzheimers Res Ther       Date:  2019-06-29       Impact factor: 6.982

4.  Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.

Authors:  Xincui Fang; Jing Zhang; Jianping Zhao; Litao Wang
Journal:  J Healthc Eng       Date:  2022-03-25       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.